Several animal studies have further shown that administration of GLP-1RAs, before or shortly after experimentally-induced stroke, increased angiogenesis, neurogenesis and cerebral blood flow (CBF), reduced neuroinflammation, oxidative stress, excitotoxicity, BBB leakage and apoptosis, and induced dose-dependent decreases in infarct volume [60,61,62]
This category includes the largest commercial nasal drug products intranasal corticosteroids such as fluticasone propionate (Flonase), mometasone furoate (Nasonex), and triamcinolone acetonide (Nasacort)
Typical ALA dosing ranges from 300-600mg daily, often split into multiple doses due to its relatively short half-life
From this perspective, GLP-1-RAs appear as a safe treatment option
Does the clinic handle complaints well